EN
中文 EN
An NMPA approved NGS-based CDx kit solution.
Detects genetic variations (SNV, InDel, CNV, and Fusion).
Provides a comprehensive guide on therapy selection for NSCLC patients.
Taken part in more than 10 CTA studies and 4 CDx development projects.
Key Features and Benefits

● NMPA-approved NGS-based CDx kit, covering 9 lung cancer-associated genes to guide therapy selection.


● Inclusion of PIK3CA gene coverage on top of the recommended 8 genes by the guidelines.

● The detection of rare mutations.

● 30ng of DNA input from puncture biopsies.




Performance Validations
Biomarker Panels



EGFR
MET
ERBB2
KRAS
BRAF
PIK3CA
ALK
ROS1
RET



Non-small cell lung cancer (NSCLC)
EGFR、ALK、ROS1、RET、MET、ERBB2、BRAF、KRAS
Colorectal cancer (CRC)
BRAF、KRAS
Specifications
Certification
NMPA-IVD
Tests/Kit
48
Alteration detected
SNV, InDel, CNV and Fusion
Sample type
FFPE tissue
Sequencing Type
PE300
Sequencer
Illumina MiSeqDx
Download Our Product Brochure Here Contact Us
Contact Our Biopharma Team to Learn More
Biomarker Discovery & Translational Research
Clinical Trial Design & Patient Recruitment
Global Capabilities for Clinical Studies
CDx Development & Commercialization
Genomic Data Solutions
ctDNA Monitoring Portfolio
Other
I also want to receive general marketing communications from Burning Rock Dx in addition to the specific information requested here. You may unsubscribe from receiving such general marketing communications at any time.
*Required
By submitting this form, or by checking the box above the “Submit” button (if applicable), you agree that your information will be processed according to Burning Rock’s privacy policy to provide you with the information and/or general marketing communications (if applicable) you have requested here. Burning Rock Dx is committed to protecting and respecting your privacy.
Contact Our Experts
We would like to collect certain personal information about you through cookies and similar technologies in order to personalize the site for you, improve the performance of the site, and support our marketing efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your personal information in accordance with our Privacy Policy, which may include online targeted and social media advertising in some instances. You can by clicking “Reject All”, you can reject all cookies except for Strictly Necessary Cookies."